Skip to main content
Premium Trial:

Request an Annual Quote

AmoyDx, AstraZeneca Strike Ovarian Cancer Companion Diagnostic Alliance

NEW YORK — Chinese diagnostics firm AmoyDx said on Friday that it has partnered with AstraZeneca to develop a companion diagnostic for use in treating ovarian cancer patients with homologous recombination deficiency (HRD).

Specific terms of the deal were not disclosed.

The alliance follows the November announcement that the companies had agreed to collaborate on the development of molecular diagnostics for gynecological indications including ones characterized by HRD. Earlier that year, the US Food and Drug Administration approved olaparib (AstraZeneca and Merck's Lynparza) for use in combination with bevacizumab (Genentech's Avastin) as a maintenance regimen for advanced HRD-positive ovarian cancer patients who are responding to first-line platinum-based chemotherapy. 

AmoyDx and AstraZeneca have worked together on a number of other cancer-related projects, including a BRCA1 and BRCA2 gene mutation detection kit, which can be used as a companion diagnostic for olaparib and received Chinese regulatory approval in early 2019.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.